GHK-Cu — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

GHK-Cu

Also known as: GHK, glycyl-L-histidyl-L-lysine, Gly-His-Lys, copper peptide, copper tripeptide complex, glycyl-L-histidyl-L-lysine-Cu(2+), glycyl-L-histidyl-L-lysine copper(II) complex, GHK-Cu2+, Copper tripeptide, Glycyl-L-histidyl-L-lysine-Cu(II)

Endogenous copper-binding tripeptide / matrikine / cosmeceutical peptide

Not FDA-approvedLast updated: October 31, 2026Based on 39 peer-reviewed studies

What it is

GHK-Cu is a copper peptide widely used in skincare for wound healing, skin rejuvenation, and anti-aging. It works by delivering copper to skin cells and activating the processes the body uses to repair and rebuild tissue. Not FDA-approved as a drug; extensively used in cosmetics and widely studied.

The scientific side

GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, urine, and tissue that declines with age. It forms a complex with copper(II) ions (GHK-Cu), which shares copper affinity similar to the transport site on albumin. GHK-Cu activates tissue remodeling through multiple mechanisms: (1) chemoattraction of macrophages, mast cells, and capillary endothelial cells to sites of injury; (2) anti-inflammatory actions including suppression of free radicals, thromboxane formation, TNF-α, and TGF-β1, while increasing superoxide dismutase activity; (3) stimulation of collagen, elastin, glycosaminoglycan, VEGF, FGF-2, NGF, and other growth factor synthesis; (4) promotion of angiogenesis, fibroblast and keratinocyte proliferation, and nerve outgrowth. GHK-Cu modulates metalloproteinase and anti-protease activity. At the molecular level, GHK-Cu directly binds and activates SIRT1, which deacetylates FoxO3a (reducing protein degradation), Nrf2 (reducing oxidative stress), and increases PGC-1α expression to promote mitochondrial function. GHK-Cu suppresses the JAK1 and STAT3 pathways, modulates PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK signaling, and has been found to up- and downregulate at least 4,000 human genes. Copper ions facilitated by GHK-Cu activate copper-dependent proteins such as lysyl oxidase (LOX) via ATOX1-mediated transport into the Golgi apparatus, promoting collagen crosslinking and extracellular matrix remodeling. GHK also chelates and reduces copper redox activity, preventing copper- and zinc-induced protein aggregation and cell death in vitro. Copper-free GHK (apo-GHK) retains some biological effects, including increased keratinocyte proliferation and integrin expression, suggesting partial activity independent of copper coordination.

Class: Endogenous copper-binding tripeptide / matrikine / cosmeceutical peptide

Not FDA-approvedLow researchSkinCopper tripeptide-1

At a glance

What it isA natural tripeptide (glycine-histidine-lysine) bound to copper, first found in human blood in 1973.
FDA statusNot approved as a drug. A common cosmetic ingredient; FDA put injectable GHK-Cu on its compounding safety-risk list in 2023.
Used forSkin and hair products; injected for skin, healing and anti-aging, without human injection studies.
Human evidenceTopical skin studies only. No published human injection study.
Copper per dose1-2 mg carries about 160-320 micrograms of copper, under the 900 microgram daily RDA and far under the 10 mg upper limit.
SportNot listed on the 2026 WADA Prohibited List.

What is GHK-Cu?

GHK-Cu is a three-amino-acid peptide, glycyl-L-histidyl-L-lysine, carrying a copper ion. It occurs naturally in human blood; Loren Pickart first described it in 1973 as a factor in human serum that kept liver cells alive longer in culture.

It is best known as "copper peptide" in skin and hair products. Injection is a separate, newer grey-market use.

Sources: [1] [2]

How does it work?

GHK binds copper tightly and is thought to deliver it to tissues, where copper is needed by enzymes involved in collagen, antioxidant defense and wound repair. In cell and gene-expression studies, GHK changed the activity of many genes linked to tissue repair and inflammation.

Most of this evidence is from cell culture, gene databases and animals. How much reaches tissues after an injection, and what it does there in people, is not known.

Pharmacokinetics

Half-lifeNot published for injected GHK-Cu
MetabolismNot characterized in humans
ClearanceNot characterized in humans
RouteMainly topical (creams, serums); injection is unstudied

Sources: [2] [3]

Is it FDA-approved?

No. GHK-Cu is not an approved drug for any use, though it is widely sold in cosmetics.

In September 2023, FDA placed GHK-Cu for injectable routes in Category 2 for 503A compounding, writing: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." As of April 2026 it is listed under "nominated but withdrawn". It has not had an advisory committee vote.

  • WADA: Not listed on the 2026 WADA Prohibited List

Sources: [4] [5]

History

Pickart's 1973 finding, a serum tripeptide that prolonged the survival of liver cells, led to decades of work on GHK in wound healing and skin. Its main commercial path became cosmetics, where copper peptides are common in creams and serums.

Injecting GHK-Cu is recent and unregulated. It is sold as a research peptide, which is what prompted FDA's 2023 compounding safety listing for injectable routes.

Sources: [1] [2] [4]

Regulatory timeline

  1. September 29, 2023FDA places GHK-Cu (for injectable routes) in Category 2 for 503A compounding, citing immunogenicity and limited human data. Source
  2. April 2026FDA's page lists GHK-Cu under "nominated but withdrawn". Source
  3. As of October 2026Not an approved drug, and not voted on by FDA's Pharmacy Compounding Advisory Committee. Source

Side effects

There are no human injection data, so injection side effects are unknown. FDA's concern is immune reactions from aggregates and impurities, not the copper.

The copper in a typical dose is small. GHK-Cu is about 16% copper by weight, so 1-2 mg carries about 160-320 micrograms, below the 900 microgram adult RDA and well under the 10 mg/day upper limit set to prevent liver damage. People with Wilson disease or other copper-handling disorders should avoid it.

Who should not use it

  • No established contraindications for injection: it has never been studied that way.
  • Wilson disease or other copper-handling disorders: avoid added copper.
  • Pregnancy and breastfeeding: not studied for injection.

No published human injection study; human data are from topical products.

Sources: [5] [6] [3]

What does the research show?

Human studies are of topical products. In a trial after CO2 laser resurfacing, GHK-Cu skin care products did not reduce redness more than standard care, though patient satisfaction was higher.

Reviews describe wound-healing, anti-inflammatory and skin-remodeling effects in cell and animal studies, mostly from Pickart's group. No published human trial has tested injected GHK-Cu.

Studied for

  • Topical skin care, including after laser resurfacing (human)
  • Wound healing and tissue repair (cell and animal studies)
  • Gene expression in tissue repair (database studies)

Sources: [7] [2] [3]

FAQ

Has GHK-Cu been tested as an injection in humans?

No published study has. All human data are from creams and serums.

Sources: [3]

Is the copper in GHK-Cu a concern?

Not at typical doses: 1-2 mg contains about 160-320 micrograms of copper, under the 900 microgram RDA and the 10 mg/day upper limit. People with copper-handling disorders such as Wilson disease are the exception.

Sources: [6]

What has FDA said about GHK-Cu?

FDA wrote that compounded injectable GHK-Cu "may pose risk for immunogenicity" and that "there are limited data in humans to inform safety-related considerations."

Sources: [5]

Is GHK-Cu FDA-approved?

No. It is a common cosmetic ingredient but not an approved drug.

Sources: [5]

Where does GHK-Cu come from?

It occurs naturally in human blood; it was first described in 1973 as a serum factor that prolonged liver cell survival.

Sources: [1]

Is GHK-Cu banned in sport?

Not listed on the 2026 WADA Prohibited List. Athletes should still check with their anti-doping organization.

Sources: [8]

Citations

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol 1973. PMID 4349963
  2. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. PMID 29986520
  3. Mateescu DM, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026. PMID 42797253
  4. FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  6. National Academies: Dietary Reference Intakes, copper (RDA 900 micrograms/day; UL 10 mg/day based on liver damage). nap.edu/read/10026/chapter/9
  7. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
  8. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Intraperitoneal injection (IP) — used in aged mice at 15 mg/kg (PMID: 42245779)Intranasal (IN) administration — used in aged mice and 5xFAD mice at 15 mg/kg (PMID: 4076691942245779)Intracutaneous injection — Gly-His-Lys-D-Ala at 0.5 µg/kg in ratsadministered around wound site (PMID: 38345677)Topical/transdermal application — reported for cosmetic and wound care contexts (PMID: 2623673016847171)Microneedle-assisted transdermal delivery — used in in vitro and porcine models (PMID: 25690343)Injectable filler (hydroxyapatite microsphere carriersubcutaneous/soft tissue) — in mice and rats (PMID: 40716276)
Storage
No specific storage conditions for GHK-Cu are described in the reviewed abstracts. General formulation challenges noted include hydrophilicity and instability of peptide ingredients. Requires manual verification from manufacturer or compounding guidelines.
Cautions
GHK-Cu is not FDA-approved as a drug; human safety data from rigorous clinical trials are scarce across all routes of administration.,Most human evidence comes from small or incompletely characterized cosmetic studies; no large-scale controlled human safety trials have been published in the reviewed literature.,In vitro keratinocyte studies found GHK-Cu was not cytotoxic and did not significantly upregulate skin irritation biomarkers at tested concentrations; CuCl2 and Cu(OAc)2 showed higher irritancy potential than GHK-Cu. However, skin irritation potential at higher concentrations or in vivo has not been fully characterized.,GHK-Cu demonstrated biphasic dose-response in vitro (maximal GAG stimulation at 10⁻⁹ to 10⁻⁸ M; stimulation declined at higher concentrations), suggesting potential concentration-dependent effects.,Sterile technique is essential for any injectable formulation to prevent contamination; compounded peptides may lack the quality controls of approved pharmaceuticals.,GHK-Cu slightly inhibited alkaline phosphatase activity and osteocalcin production in osteoblastic cells in vitro, suggesting potential adverse effects on osteoblast differentiation at certain concentrations.

Legal & regulatory status

US FDA

Not FDA-approved as a drug; most applications remain unapproved. Multiple review articles note GHK-Cu is not FDA-approved and lacks rigorous clinical trial validation. One review notes GHK-Cu is categorized among…

WADA

Not listed on the 2026 WADA Prohibited List.

Health Canada

Not stated in reviewed literature — requires manual verification